Chargement en cours...
Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
Chimeric antigen receptor (CAR) T cell therapy can achieve outstanding response rates in heavily pretreated patients with hematological malignancies. However, relapses occur and they limit the efficacy of this promising treatment approach. The cellular composition and immunophenotype of the administ...
Enregistré dans:
| Publié dans: | Int J Mol Sci |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6940894/ https://ncbi.nlm.nih.gov/pubmed/31835562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20246223 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|